Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.37 |
| ▸ | PSIP1 | O75475 | 3/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6425777 | 0.94 | AKR1C3 (0.36) | AKR1C3AKR1C2PSIP1SRCLMNA | |
| SCHEMBL6423408 | 0.94 | AKR1C3 (0.40) | AKR1C3AKR1C2SRCPPARGPPARA | |
| SCHEMBL6424946 | 0.92 | AKR1C3 (0.45) | AKR1C3AKR1C2LMNAMAPTPPARG | |
| SCHEMBL6424835 | 0.92 | SRC (0.40) | AKR1C3AKR1C2SRCMAPTHTT | |
| SCHEMBL6423833 | 0.92 | AKR1C3 (0.45) | AKR1C3AKR1C2LMNAMAPTPPARG | |
| SCHEMBL6423618 | 0.92 | AKR1C3 (0.39) | AKR1C3AKR1C2SRCLMNAMAPT | |
| SCHEMBL6427009 | 0.91 | AKR1C3 (0.35) | AKR1C3AKR1C2SRCPPARGPPARA | |
| SCHEMBL6426944 | 0.91 | AKR1C3 (0.35) | AKR1C3AKR1C2SRCPPARGPPARA | |
| SCHEMBL6426675 | 0.90 | SRC (0.43) | AKR1C3AKR1C2SRCBCL2MDM2 | |
| SCHEMBL6424736 | 0.90 | PSIP1 (0.36) | PSIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | AKR1C3 577/4885AKR1C2 563/4885PSIP1 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.